Merus (MRUS) Stock Overview
A clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MRUS Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Merus N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$94.89 |
| 52 Week High | US$95.04 |
| 52 Week Low | US$33.19 |
| Beta | 1.26 |
| 1 Month Change | 39.19% |
| 3 Month Change | 50.00% |
| 1 Year Change | 80.09% |
| 3 Year Change | 319.13% |
| 5 Year Change | 626.57% |
| Change since IPO | 845.12% |
Recent News & Updates
Recent updates
Genmab Buys Merus For $8bn: A Good Deal If Potential Is Converted Into Revenue
Sep 29Need To Know: The Consensus Just Cut Its Merus N.V. (NASDAQ:MRUS) Estimates For 2025
Mar 05
Earnings Update: Merus N.V. (NASDAQ:MRUS) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts
Mar 02Here's Why We're Not Too Worried About Merus' (NASDAQ:MRUS) Cash Burn Situation
Feb 16Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff
Jan 20Merus: Petosemtamab Set Up For December 2024 Data Presentation
Nov 05Merus N.V.'s Innovative Cancer Therapies: Balancing Its IP Potential With Financial Risks
Aug 14Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)
May 24Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement
Mar 01Merus Stock: Rally Seems Overdone
Jan 23Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M
Aug 08Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies
Aug 02Merus: Precision Oncology Pioneer Continues To Execute In The Clinic
Jun 30Shareholder Returns
| MRUS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.6% | 2.8% | 1.7% |
| 1Y | 80.1% | 0.1% | 14.5% |
Return vs Industry: MRUS exceeded the US Biotechs industry which returned 0.1% over the past year.
Return vs Market: MRUS exceeded the US Market which returned 14.5% over the past year.
Price Volatility
| MRUS volatility | |
|---|---|
| MRUS Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MRUS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MRUS's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 291 | Bill Lundberg | www.merus.nl |
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors.
Merus N.V. Fundamentals Summary
| MRUS fundamental statistics | |
|---|---|
| Market cap | US$7.19b |
| Earnings (TTM) | -US$385.52m |
| Revenue (TTM) | US$56.23m |
Is MRUS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRUS income statement (TTM) | |
|---|---|
| Revenue | US$56.23m |
| Cost of Revenue | US$109.05m |
| Gross Profit | -US$52.82m |
| Other Expenses | US$332.70m |
| Earnings | -US$385.52m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.09 |
| Gross Margin | -93.94% |
| Net Profit Margin | -685.64% |
| Debt/Equity Ratio | 0% |
How did MRUS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/17 21:23 |
| End of Day Share Price | 2025/10/17 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Merus N.V. is covered by 30 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Venezia | Alliance Global Partners |
| Etzer Darout | Barclays |
| Evan Seigerman | BMO Capital Markets Equity Research |